Regulus Therapeutics (RGLS) Hits New 52-Week Low at $1.83

Share on StockTwits

Regulus Therapeutics Inc (NASDAQ:RGLS) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $1.83 and last traded at $1.90, with a volume of 426 shares trading hands. The stock had previously closed at $1.92.

A number of equities research analysts recently issued reports on RGLS shares. Leerink Swann lowered Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 10th. Wedbush reaffirmed a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a research note on Friday, August 10th. B. Riley reduced their target price on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating on the stock in a research note on Friday, July 6th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Saturday, October 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Friday, August 10th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $1.42.

The company has a market cap of $17.46 million, a PE ratio of -0.17 and a beta of 1.37.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. On average, equities analysts forecast that Regulus Therapeutics Inc will post -5 EPS for the current year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. A.R.T. Advisors LLC purchased a new position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned 0.16% of Regulus Therapeutics as of its most recent SEC filing.

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: Marijuana Stocks Investing Considerations

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

St. James’s Place plc  Receives GBX 1,300.30 Average Price Target from Analysts
St. James’s Place plc Receives GBX 1,300.30 Average Price Target from Analysts
Gnosis  Tops 24-Hour Volume of $400,528.00
Gnosis Tops 24-Hour Volume of $400,528.00
FNKOS Reaches Market Cap of $1.03 Million
FNKOS Reaches Market Cap of $1.03 Million
Etrion  Sets New 12-Month Low at $0.20
Etrion Sets New 12-Month Low at $0.20
TransEnterix, Inc.  Short Interest Up 0.6% in November
TransEnterix, Inc. Short Interest Up 0.6% in November
Cleveland-Cliffs Inc  Given Average Recommendation of “Hold” by Brokerages
Cleveland-Cliffs Inc Given Average Recommendation of “Hold” by Brokerages


© 2006-2018 Ticker Report